Share Name Share Symbol Market Type Share ISIN Share Description
Belluscura Plc LSE:BELL London Ordinary Share GB00BD3B8Z11 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  3.50 4.12% 88.50 40,945 16:15:12
Bid Price Offer Price High Price Low Price Open Price
85.00 92.00 88.50 86.00 86.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 310.81 -3.86 -0.04 102
Last Trade Time Trade Type Trade Size Trade Price Currency
16:06:05 O 5,000 86.20 GBX

Belluscura (BELL) Latest News

More Belluscura News
Belluscura Investors    Belluscura Takeover Rumours

Belluscura (BELL) Discussions and Chat

Belluscura (BELL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-06-24 15:06:0686.205,0004,310.00O
2022-06-24 15:06:0586.205,0004,310.00O
View all Belluscura trades in real-time

Belluscura (BELL) Top Chat Posts

Belluscura Daily Update: Belluscura Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker BELL. The last closing price for Belluscura was 85p.
Belluscura Plc has a 4 week average price of 83p and a 12 week average price of 83p.
The 1 year high share price is 151.50p while the 1 year low share price is currently 54p.
There are currently 115,306,407 shares in issue and the average daily traded volume is 90,676 shares. The market capitalisation of Belluscura Plc is £102,046,170.20.
brummy_git: The very best investment opportunities still attract capital. All the news & commentary here wrt Belluscura's £6m over-subscribed placing today at 85p.;utm_medium=member_desktop_web
maytrees: Presumably TEK share price will show some gain too if this BELL share price gain continues.
buywell2: USA Government Agency Contract Belluscura is awarded a Distribution and Pricing Agreement ("DAPA") from the United States Defense Logistics Agency ("DLA") for the X-PLOR LONDON, U.K. AND PLANO, TX, U.S. (7 April 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the X-PLOR portable oxygen concentrator has been awarded a Distribution and Pricing Agreement ("DAPA") code from the U.S. Defense Logistics Agency ("DLA") through our distribution partner, Lovell Government Services Inc ("Lovell"). DLA procures items from manufacturers and suppliers and provides them to the Department of Defense and other federal/state customers throughout the US and globally. DLA procures more than $41.8 billion in goods and services annually on behalf of its customers. Lovell is a Service-Disabled Veteran-Owned military purchasing organisation Small Business whose primary mission is to provide exclusive medical, surgical, and pharmaceutical resources to the U.S. Department of Defense and Veterans Affairs Medical Organizations. Lovell has already commenced selling the X-PLOR. Robert Rauker, Chief Executive Officer, Belluscura plc, commented: "Receiving the DAPA code opens up a significant sales opportunity for the X-PLOR as it is now available through the DLA system which includes the military installations, military hospitals and other federal and state agencies serviced by the DLA ." ----------------------------------------------------------------------------------------------------- The Belluscura products are much, much lighter than the oxygen concentrators that are currently used by the USA armed forces in battlefield situations buywell has posted about this previously --- A HUGE opportunity Perhaps there is now imo a chance of USA Armed forces contracts for the new models soon to be released ------------------------------------------------------------------------------------------------------ Posted on the TEK thread buywell2 - 27 Apr 2021 - 22:24:13 - 1633 of 2696 TEK - TekCapital: Profit from University Intellectual Property - TEK The USA Military is indeed currently testing a new battlefield portable oxygen concentrator that weighs 12 pounds FOUR times the weight of the Belluscura portable oxygen concentrator One would like to think that Belluscura and Tekcapital have made the US Military aware of the specification of the FDA cleared Belluscura unit , and have asked to tender for what is clearly going to be a major upgrade (contract) for new battlefield portable oxygen concentrators htTps:// dyor
maytrees: Good morning Decent share price gain for BELL so far today though maybe simply because BELL share price recent fall was overdone.
buywell3: It is not a one product company They have two more oxygen concentrators due to come our soon hTtps:// The Patents/IP that they own also allow a much larger oxygen concentrator could be produced, several of which could supply a hospital and avoid having supply issues They also have patents pending for the use of their technology in hospital settings/treatments which use additional Belluscura products and technology --- example In the new developing area of extracorporeal carbon dioxide removal (“ECCO2R”) so as to support the respiratory system. The potential advantages of ECLS for respiratory failure include the ability to rest the lungs by avoiding injurious mechanical ventilator use Plus another patent pending that is in the area concerning new systems and methods for improving patient recovery postoperatively by using Belluscura oxygen concentrators together with a Belluscura level of consciousness monitor whereby a Belluscura central processor includes a sleep database having baseline sleep information for the generic patient and the Belluscura oxygen concentrator is configured to provide a flow of concentrated oxygen to the patient as required regarding the patient's state of wakefulness, awareness and alertness And others --- If you cast your minds back then you might recall one of the BELL appointees last year came from a much larger USA competitor ---- Mkt Cap in the $ Billions BELL is set to make major inroads into the USA market of portable oxygen concentrators in 2022 with what many would call their disruptive technology The light weight of their units coupled with battery longevity and modular design also might well attract the attention of the Armed forces of some countries as it is significantly better than what is being used now. Modular design means that spares can be more easily carried and used so as to keep oxygen concentrators working in front line conditions imo dyor
maytrees: Anyway the BELL share price is up again (so far) and earlier than usual today.
maytrees: Good morning BELL share price still holding up; probably the good news in USA continues but we shall see.
maytrees: Good morning The shortage of stock point made a day or two back may be correct. The BELL share price is so far today, up despite sells.
stuffee: Hedgehog, Could I suggest in terms of comparisons, Inogen is interesting. Inogen is the principal competitor to Bell with a 26% US market share. Bell's X-PLO2R device is considered lighter, more powerful, quieter and more convenient than Inogen's principal G3 device. I suggest it could become the market leader within two years; this view was perhaps shared by Inogen's former Operations Director, Keith Cook, who left the company in June to join Bell. Inogen was established 20 years ago and has been quoted on NASDAQ for 7 years and is exclusively involved in the supply of POCs. It reported sales of $100m for the quarter to 30 June 2021 with net income of $5m. It has a present market cap of $1bn. Bell issued a pretty encouraging trading update earlier this month, (which I couldn't find on RNS). Chief Executive Bob Rauker stated: "I am extremely pleased to announce that the group has achieved its target timeframe and distributed the first X-PLO2RTM units off the production line to customers on September 3. Initial demand for X-PLO2RTM has been strong. To date we have received orders that meet this year's forecast unit sales and expect to exceed the forecast in the coming months." Looking ahead, will up production with market demand. Bell, even after its recent impressive share price performance, has a market cap of just £120m. If Bell's sales performance meets expectation, I suggest it could become as valuable as Inogen.
hedgehog 100: "A smart technology play offering material upside A little known small-cap investment company focused on high growth technologies in food technology, autonomous vehicles, smart eyewear and respiratory medical devices has delivered eye-catching valuation gains. August 19, 2021 By Simon Thompson • NAV surges 56 per cent to US$51m in latest six-month period. • Value of 15 per cent stake in Belluscura has since soared 70 per cent to £15.4m since the half year-end. • Portfolio company, Lucyd, launches crowdfunding at double Tek’s pre-money valuation in its interim accounts. TekCapital (TEK:22.25p), a £29.1m market capitalisation company that holds a concentrated investment portfolio focused on high growth technologies in the food technology, autonomous vehicles, smart eyewear and respiratory medical devices, has released eye-catching interim results. Net asset value (NAV) surged 56 per cent to US$51.1m (39c a share) in the six months to 31 May 2021, buoyed by a thumping US$8.6m (£6.2m) paper gain on Tek’s pre-IPO holding of 17.1m shares in recently floated Belluscura (BELL: 90p), an Aim-traded company that is developing and commercialising IP in the medical devices space. Belluscura's first product, the X-PLO₂RTM, is a lightweight FDA cleared portable oxygen concentrator (POC) that has been designed to replace larger, metal oxygen tanks and heavier POC devices. Weighing less than 1.5kg, it is the world's first modular POC and generates more oxygen by weight than any other FDA cleared POC in its class. The World Health Organisation (WHO) estimate that 328m people globally have Chronic Obstructive Pulmonary Disease (COPD), of whom 65m have moderate or severe symptoms and 90 per cent are typically middle-aged or older adults who smoke. COPD is the third leading cause of death in the world, symptoms being breathlessness, a persistent chesty cough, frequent chest infections and persistent wheezing. Analysts estimate the POC market could be worth US$2.4bn (£1.75bn) within three years, up from US$1.66bn in 2020, a high growth market and one that is growing even faster due to Covid-19. Indeed, WHO plans to purchase 184,000 units at a cost of over US$100m to distribute worldwide, having so far distributed over 30,000 concentrators and 40,000 pulse oximeters and patient monitors across 121 countries. The medical portable O2 market is expected to grow to US$2.4bn by 2024 2018 2019 2020 2021E 2022E 2023E 2024E Revenue $1.40bn $1.51bn $1.66bn $1.83bn $2.01bn $2.21bn $2.41bn Source: Global Insights Importantly, X-PLO₂RTM offers cost benefits to users, too. That’s because they can swap out the filter cartridges to enable higher capacity oxygen flow without having to buy a new device; like upgrading memory on a laptop. The result is significantly more affordable oxygen therapy for the life of the patient. Belluscura's management team plan to spend £3m of the £17.5m proceeds raised in May’s IPO launching X-PLO₂R – the first units will be distributed before the end of September and the company has four distribution agreements in place across East and MidWest America. A further £8m is earmarked to progress additional products within the range for launch later this year and early in 2022. Investors have been cottoning onto Belluscura's progress, hence why its share price has soared 70 per cent from 53p to 90p since Tek’s half year-end, the effect of which is to add a further US$8.3m (6.3c a share) to the company’s NAV. ... Tek’s 15 per cent stake in Belluscura is now worth £15.4m, or more than half Tek’s own market capitalisation of £28.8m. There is ample scope for further valuation gains, too. That’s because Belluscura's house broker Dowgate Capital believes that by 2023 the £103m market capitalisation company will reach profitability and be cashflow positive based on 12,000 units sales. Having hit that inflexion point, analysts are predicting the company could be selling 22,000 units (based on 5 per cent share of the POC market) in 2024 to produce revenue of US$47.9m, cash profit of US$11.4m and earnings per share (EPS) of 6.5p. With gross margin around 50 per cent, the operational gearing of the business is such that profits and EPS would treble in 2025 based on 50,000 unit sales. Belluscura financial forecasts 2021 to 2025 2021E 2022E 2023E 2024E 2025E Units sold 150 2,000 12,000 22,000 50,000 Revenue $0.2m $3.0m $19.8m $47.9m $109.9m Ebitda -$2.3m -$4.6m $1.1m $11.4m $33.5m EPS na na 0.1p 6.5p 18.2p PE na na na 8 3 Net cash $17.4m $9.8m $7.9m $17.3m $44.6m Source: Dowgate Capital (27 July 2021) ..."
Belluscura share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220625 11:02:35